| Bioactivity | FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research[1][2]. |
| Invitro | MAO-A and MAO-B act function to lower central nervous system (CNS) concentration of monoamines, regulate the amount and activity of available monoamines[1].If dopamine levels are too high, MAO levels will increase to compensate. If serotonin levels are too low, then MAO activity will decrease to leave adequate serotonin supplies for the CNS to function optimally[1].FTEAA inhibits MAO-A and MAO-B with micromolar scale IC50s of 0.52 and 1.02 μM, respectively[2]. |
| In Vivo | FTEAA exhibits total clearance of 0.446 log/mL/min/kg, and the tolerable dose is prescribed to be 0.513 log mg/kg/day[2].Predicted Pharmacokinetic Analysis of FTEAA[2]Intestinal Absorption (%) |
| Name | FTEAA |
| Formula | C34H26F8N2O2 |
| Molar Mass | 646.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bilal AK, et al. Exploring Highly Functionalized Tetrahydropyridine as a Dual Inhibitor of Monoamine Oxidase A and B: Synthesis, Structural Analysis, Single Crystal XRD, Supramolecular Assembly Exploration by Hirshfeld Surface Analysis, and Computational [2]. Schwartz TL, et al. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr. 2013 Dec;18 Suppl 1:25-32; quiz 33. |